Vanderbilt University Anti-Inflammatory Therapy Licensed to Amytrx is Now in Clinical Trials for Eczema Treatment
October 28, 2020
October 28, 2020
NASHVILLE, Tennessee, Oct. 28 (TNSRes) -- Vanderbilt University issued the following news:
A cell-penetrating, anti-inflammatory peptide developed by Jacek Hawiger, Louise B. McGavock Chair and Distinguished Professor of Medicine, and licensed to biopharmaceutical company Amytrx, has been approved by the FDA for testing as a potential therapeutic for mild to moderate eczema. The peptide, known as AMTX-100, has been in clinical trials since March.
The licensing agreement . . .
A cell-penetrating, anti-inflammatory peptide developed by Jacek Hawiger, Louise B. McGavock Chair and Distinguished Professor of Medicine, and licensed to biopharmaceutical company Amytrx, has been approved by the FDA for testing as a potential therapeutic for mild to moderate eczema. The peptide, known as AMTX-100, has been in clinical trials since March.
The licensing agreement . . .